CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
CP-690,550 +3 moredrug
Likely dose
CP-690,550 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01740362
NCT01740362Phase 1Completed
CompareCT.gov

Phase 1, Open-Label Study To Evaluate Single Dose Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Patients With Impaired Renal Function

Pfizer·interventional·Posted Dec 4, 2012·Updated Jan 7, 2013

In Brief

A Phase 1 clinical trial evaluating CP-690,550 for Renal Impairment. Completed, enrolled 24 participants across 4 sites.

Detailed Summary

A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Impairment
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 4, 2012
Enrollment StartOct 1, 2003
Primary CompletionMar 1, 2004
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 13.6 years ago

Interventions

CP-690,550drug

10 mg (2 x 5 mg tablets), single dose

CP-690,550drug

10 mg (2 x 5 mg tablets), single dose

CP-690,550drug

10 mg (2 x 5 mg tablets), single dose

CP-690,550drug

10 mg (2 x 5 mg tablets), single dose